Literature DB >> 1234632

Epithelial carcinoma of the ovary:prognostic importance of histologic grade.

T G Day, H S Gallager, F N Rutledge.   

Abstract

Although this report contains only a few cases of epithelial carcinoma of the ovary and is not complete, it does suggest several new points and confirms other points reported in the literature: 1) increasing stage of cancer correlates well with decreased survival; 2) higher histologic grade of cancer correlates with decreases survival; 3) patients with a given stage of ovarian cancer having higher grades of malignancy have poorer survival; and 4) lower grade tumors are most frequently associated with lower stages of cancer, and higher grade tumors are most frequently associated with advanced stages.

Entities:  

Mesh：

Year:  1975        PMID： 1234632

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN： 0083-1921


  14 in total

1.  Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.

Authors:  A Reles; A Schmider; M F Press; I Schönborn; W Friedmann; S Huber-Schumacher; T Strohmeyer; W Lichtenegger
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  A CA125 score as a prognostic index in patients with ovarian cancer.

Authors:  A Rosen; P Sevelda; M Klein; J Spona; A Beck
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

3.  The value of second-look operation in patients with advanced epithelial ovarian carcinoma.

Authors:  P Sevelda; C Dittrich; H Salzer
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

4.  Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1.

Authors:  B M Kacinski; D Carter; K Mittal; L D Yee; K A Scata; L Donofrio; S K Chambers; K I Wang; T Yang-Feng; L R Rohrschneider
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

5.  Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Authors:  Jane Bayani; Paula Marrano; Cassandra Graham; Yingye Zheng; Lin Li; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-08-11       Impact factor: 6.603

6.  Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.

Authors:  C Sessa; G Bolis; N Colombo; M D'Incalci; B Mermillod; I Valente; C Mangioni
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.

Authors:  S J C Shan; A Scorilas; D Katsaros; E P Diamandis
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

8.  A comparative analysis of management and prognosis in stage I and II fallopian tube carcinoma and epithelial ovarian cancer.

Authors:  A C Rosen; P Sevelda; M Klein; A H Graf; M Lahousen; A Reiner; L Auerbach; N Vavra; H R Rosen
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

9.  First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.

Authors:  A Rosen; P Sevelda; M Klein; K Dobianer; C Hruza; K Czerwenka; H Hanak; N Vavra; H Salzer; S Leodolter
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

10.  TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.

Authors:  M Medl; E Ogris; C Peters-Engl; S Leodolter
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.